Abnormal uterine bleeding (AUB) is a clinical entity that has been defined as presence of irregular menstrual bleeding without diagnosing any particular organic lesion. It is considered to be a diagnosis of exclusion, without any pathologic entity⁴. Even though numerous causes has been found out for the abnormal uterine bleeding in women, the endometrial hyperplasia and carcinoma remains the most common causes⁵. The importance of ruling out or treating these conditions is due to high incidence of mortality  and morbidity encountered with the patients having theseconditions.  Many studies have revealed that the endometrial hyperplasia act as precursor for the development of the endometrial carcinoma, in particular endometrioid type of endometrial carcinoma^1,2.

AIM:

In this study, an anti–apoptotic marker Bcl–2 has been used. Bcl–2 expression has been immunohistochemically assessed in various endometrial tissue such as cyclical endometrium, endometrial hyperplasia and endometrial carcinoma.

OBJECTIVES:

To determine the expression of Bcl–2.In cyclical endometrium in the proliferative and secretory phases, endometrial hyperplasia, endometrial carcinoma.

CONCLUSION:

In hyperplasia, Bcl–2 expression is increased in an increasing fashion from simple hyperplasia to complex hyperplasia without atypia and to complex hyperplasia  with atypia. This is as a result of unopposed effect of the estrogen in the hyperplastic endometrial tissue^1,2. Findings of this study reveals that Bcl–2 can be used as a  potential therapeutic agent.